Search the Newsreel

Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MapLight Therapeutics, Inc. (NASDAQ:MPLT) after the company's shares fell over 50% due to mixed Phase 2 trial results for its schizophrenia drug candidate. The firm encourages investors who purchased MapLight …

Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 22,082 Shares of Stock

Maplight Therapeutics (NASDAQ:MPLT) insider James Woodruff Lillie sold 22,082 shares of the company's stock, valued at approximately $276,908, as part of a pre-arranged trading plan. This transaction reduced his direct ownership by 9.84%. Despite reporting an earnings miss, analysts generally maintain a "Buy" rating …

Form 13D/A MapLight Therapeutics For: 3 August By Investing.com

This article from Investing.com announces the filing of Form 13D/A by MapLight Therapeutics for August 3rd. The content is primarily a placeholder for this regulatory filing, indicating its publication date and the company it pertains to. It does not provide further details about the …

What's Maplebear's Probability of an Earnings Beat This Season?

With Maplebear Inc. CART, doing business as Instacart, set to report its second-quarter 2026 earnings results on Aug. 6, after the market closes, investors are asking an important question: Can the company return to its earnings-beat track after last quarter's slight miss, or will …

Microba Life Sciences (ASX:MAP) Rises as SYNLAB Expands the Diagnostics Route

What Maplebear (CART)'s First UK Caper Smart Trolley Partnership with Morrisons Means For Shareholders

In late July 2026, Instacart and Morrisons introduced AI-powered Caper smart trolleys at Morrisons' Preston supermarket, Instacart's first UK retail partnership for this technology, enabling automatic item recognition, on-the-spot produce weighing, budget tracking, loyalty integration, and faster checkout through dedicated Caper lanes. The rollout …

Maplebear (CART) Launches UK Smart Trolleys As Fair Value Narrative Stays In Focus

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Instacart parent Maplebear (CART) is drawing attention after launching its AI-powered Caper smart trolleys with UK grocer Morrisons, the company's first British retail partnership for …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against MapLight Therapeutics, Inc. (MPLT) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against MapLight Therapeutics, Inc. (MPLT) after its shares significantly dropped due to mixed Phase 2 trial results for its schizophrenia drug candidate. The firm encourages investors who purchased MapLight securities to learn …

Maplight Therapeutics (MPLT) insider plans sale of 22,082 shares from vested RSUs

James Lillie, an insider at Maplight Therapeutics, Inc. (MPLT), plans to sell up to 22,082 shares of common stock through Jefferies LLC, with an aggregate market value of $287,507.64. These shares are related to vested Restricted Stock Units (RSUs) from July 18, 2025, and …

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP is investigating MapLight Therapeutics, Inc. (MPLT) for potential securities law violations after the company's shares dropped over 50% due to mixed Phase 2 trial results for its schizophrenia drug candidate. The investigation focuses on whether MapLight made false or …

ETFs Investing in Maplebear Inc. Stocks

This article lists various ETFs that hold Maplebear Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return for each fund. The purpose is to help investors find …

Maplight Therapeutics (NASDAQ:MPLT) Rating Lowered to Strong Sell at Wall Street Zen

Deutsche Bank Adjusts Maplebear Price Target to $45 From $41, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Maplebear (Instacart) to $45, an increase from its previous target of $41. Despite this upward revision, the bank has maintained its "Hold" rating on the company's stock. This news was released on July 31, 2026, at …

Mapletree Pan Asia Commercial Trust (SGX:N2IU) Stock Faces Margin Compression And Debt Strain

MapLight shares sink on mixed ph. 2 schizophrenia readout

MapLight Therapeutics' shares plummeted over 60% after revealing mixed results from its phase 2 Zephyr trial for schizophrenia treatment ML-007C-MA. While a twice-daily dose met its primary endpoint by significantly reducing disease severity, a once-daily dose did not achieve statistical significance, although it showed …

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 9.2% - What's Next?

Maplight Therapeutics (NASDAQ:MPLT) saw its shares drop by 9.2% to $13.64 with high trading volume. This decline follows the company reporting a quarterly loss of $1.34 per share, missing analyst estimates. Despite the drop and mixed insider trading activity, the stock maintains an average …

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has received an average "Buy" recommendation from seventeen research firms, with most analysts issuing buy or strong-buy ratings, despite some recent downward adjustments to price targets. The company's shares opened at $15.02, with a market capitalization of $640.12 million, and …

Maplebear stock may move 9.2% on earnings release

Maplebear Inc. (CART) stock is projected to move by 9.2% following its upcoming earnings release on August 6, according to options data analyzed by Bloomberg. Historically, the actual price movement has exceeded the options-implied move in three out of the last eight earnings announcements. …

Maplebear Number of Employees 2026 | Employee Count & Headcount Data

Maplebear, Inc. (CART) had approximately 3,938 employees worldwide as of March 2026, marking a 5.5% growth from 2023, though a 2.2% decline year-over-year in 2026. The company is actively hiring with 1,205 job postings in 2026, a 64% decline from 2025. Its workforce is …

Laba MAPA Melonjak 32% Jadi Rp865 Miliar, Apa yang Mendorong Kinerja MAP Aktif Adiperkasa?

Intermap Technologies to Acquire PCI Geomatics in Cash Deal, Boosting AI-Powered Geospatial Platform

Maple Leaf Foods (TSX:MFI) Attracts Consumer Staples Interest

Maplebear (CART) Earnings Expected to Grow: Should You Buy?

Maplebear (CART) Could Be 23% Overvalued On Its UK Caper Trolley Debut

Maplebear (Instacart) has launched AI-powered Caper smart trolleys in a UK Morrisons supermarket, marking its first international retail deployment. While the company shows mixed stock performance with recent revenue growth, a narrative suggests it is 23.4% overvalued at $37 per share compared to its …

MapLight CEO on what investors missed in the biotech’s schizophrenia data

MapLight Therapeutics CEO Christopher Kroeger expressed surprise at the market's negative reaction to their schizophrenia drug data, which led to a two-thirds drop in market value despite positive results. He argues that investors are overly focused on a direct comparison of PANSS scores with …

Maplebear Chief Legal Officer Morgan Fong Sells 18,390 Shares for $815,400

Morgan Fong, Chief Legal Officer of Maplebear (Instacart), sold 18,390 shares for $815,400 after exercising stock options. This transaction was part of a pre-planned trading strategy and represents a small portion of Fong's total holdings, indicating it's likely for personal reasons rather than a …

Mapletree Logistics Trust (SGX:M44U) Stock Can Margins Offset DPU Strain

ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT

ADAR1 Capital Management LLC has acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT), purchasing 374,909 shares valued at approximately $7.6 million. This move comes as Maplight Therapeutics faces mixed trial results for its ML-007C-MA drug, with the twice-daily dose showing promise but the …

Maplight Therapeutics (NASDAQ:MPLT) Shares Up 18.2% Following Insider Buying Activity

Microba Life Sciences Releases 8.15 Million Shares at 5 Cents Following Shareholder Approval

Mapletree Industrial Trust (SGX:ME8U) Reports Softer Quarterly Earnings, Is It Still Cheap?

Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $148,702.40 in Stock

Maplight Therapeutics Director Troy Cox purchased 15,620 shares of the company's stock for $148,702.40 on July 28, 2026, increasing his ownership significantly. This insider acquisition comes as Maplight shares rose 24.3%, despite recent negative news regarding a trial setback and a quarterly loss. The …

Instacart’s UK Smart Trolley Debut With Morrisons Might Change The Case For Investing In Maplebear (CART)

Instacart (Maplebear) has launched AI-powered Caper smart trolleys at a Morrisons store in the UK, marking its first international retail partnership for this technology. This initiative demonstrates Instacart's strategy to expand its Connected Stores technology globally and integrate online personalization, budgeting tools, and retail …

MapLight Therapeutics recovers a portion of Monday's 73% rout (MPLT:NASDAQ)

MapLight Therapeutics (MPLT) saw its shares rise 23% on Wednesday, partially recovering from a 73% drop the previous day. The initial collapse was due to mixed Phase 2 results for its schizophrenia drug candidate. The company focuses on central nervous system disorders.

Maplight Therapeutics (NASDAQ:MPLT) Sees Unusually-High Trading Volume - Time to Buy?

Maplight Therapeutics (NASDAQ:MPLT) experienced an unusually high trading volume, with shares surging by 982% following positive Phase 2 ZEPHYR trial results for its schizophrenia treatment ML-007C-MA. Despite a consensus "Buy" rating and a target price of $34.42 from analysts, the company recently missed quarterly …

HC Wainwright Issues Pessimistic Forecast for Maplight Therapeutics (NASDAQ:MPLT) Stock Price

HC Wainwright has lowered its price target for Maplight Therapeutics (NASDAQ:MPLT) to $26 from $45, while retaining a "buy" rating, indicating a potential 162.63% upside despite the stock opening down 72.9% at $9.90. The company recently reported a quarterly EPS loss of $1.34, missing …